Safety, Immune and Clinical Responses in Metastatic Melanoma Patients Vaccinated With a Long Peptide Derived From Indoleamine 2,3-Dioxygenase in Combination With Ipilimumab

Bjoern et al., Cytotherapy (2016) - PMID: 27378345

Product(s) used in this publication:  Custom Peptide Synthesis



Indoleamine2,3-dioxygenase (IDO) is an emerging new target in cancer therapy that can be targeted with active immunotherapy (e.g. through peptide vaccination). Furthermore, IDO has been identified as a key mechanism underlying resistance to treatment with the checkpoint blocking antibody ipilimumab (ipi).


Ten patients with metastaticmelanoma participated in a phase I first-in-human clinical study assessing safety of combining ipi with a 21-mer synthetic peptide vaccine from IDO denoted IDOlong. Secondary and tertiary end points included vaccine and clinical response.


Treatment was generally safe and well tolerated. Vaccine related adverse reactions included grade I and II erythema, oedema and pruritus at the vaccination site, which were manageable with mild topical corticosteroids. One patient developed presumed ipi-induced colitis. It initially responded to high-dose parenteral corticosteroids but later relapsed while the patient was admitted to a local hospital, where he died after receiving suboptimal therapy. Vaccine-specific T-cell responses were detectable ex vivo in three patients. At first evaluation, five of the 10 treated patients were in stable disease, one of whom had an unconfirmed partial response.


Treatment with IDOlong synthetic peptide vaccine in combination with ipi was generally safe and without augmented toxicity. The vaccine induced readily detectable T-cell responses in a subset of patients. Treatment showed signs of clinical activity, although not exceeding efficacy of ipi alone. Results should be confirmed in a larger study.

Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.


IDO; Indoleamine2,3-Dioxygenase; Ipilimumab; Melanoma; Peptide vaccine

Stay in touch and be the first to receive the latest news!